logo
Plus   Neg
Share
Email

6 Top Losers In Healthcare Sector (EDIT, RNN, COCP...)

pharmadown-jan22-lt.jpg

The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. Editas Medicine Inc. (EDIT)

Lost 19.85% to close Tuesday's (Jan.22) trading at $20.95.

News: The Company announced that Katrine Bosley has decided to step down from her role as President and CEO, effective March 1, 2019. Bosley has also resigned from the Company's Board of Directors.

2. Rexahn Pharmaceuticals Inc. (RNN)

Rexahn Pharma is a clinical-stage biopharmaceutical company developing novel, targeted therapeutics for the treatment of cancer.

Lost 19.20% to close Tuesday's trading at $1.01.

News: The Company announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.

Oppenheimer & Co. Inc. is acting as sole book-running manager for the offering.

3. Microbot Medical Inc. (MBOT)

Microbot Medical is a medical device company specializing in the design and development of transformational micro-robotic medical technologies.

Lost 16.28% to close Tuesday's trading at $7.20.

News: No news

Recent event:

On January 14, the Company announced encouraging results from an independent in-vitro study of its Self-Cleaning Shunt, or SCS, for treating Hydrocephalus, also known as "water in the brain".

Near-term Catalyst:

A follow-up study in both in-vitro (lab) and in-vivo (animal) models is underway, with data expected in the second half of 2019.

4. Oasmia Pharmaceutical AB (OASM)

Oasmia Pharma is a Swedish pharmaceutical company developing new generation of drugs within the fields of human and veterinary oncology.

Lost 20.31% to close Tuesday's trading at $2.59.

News: The board of directors of the Company has resolved to cancel the extraordinary general meeting which was to be held January 25, 2019.

On December 14, 2018, the Company announced a notice to an extraordinary general meeting, at the request of its largest shareholder, Arwidsro Investment AB and Per Arwidsson (jointly"Arwidsro").

The background for Arwidsro's request to issue the notice to an extraordinary general meeting is the dispute regarding 23,225,806 of Oasmia's warrants of series 2018/2019, which Arwidsro claims it is entitled.

5. Cocrystal Pharma Inc. (COCP)

Lost 15.80% to close Tuesday's trading at $3.25.

News: The Company announced safety and preliminary efficacy data for its U.S. phase IIa study of CC-31244 for the ultra-short treatment of HCV infected individuals.

Eight of 12 subjects achieved the primary efficacy endpoint of sustained virologic response at 12 weeks after completion of treatment, and that equates to 66%. The sustained virologic response rate associated with the currently approved HCV therapies is more than 90%.

There is currently no approved HCV therapy of 6 weeks duration or less, noted the Company.

The data obtained from Cocrystal Pharma's trial used 2 weeks of CC-31244 in combination with Gilead's approved HCV drug Epclusa. Following this, the subjects continued Epclusa treatment alone for another 4 weeks.

Near-term Catalyst:

A phase IIa study in Hong Kong evaluating the safety, tolerability and preliminary efficacy of CC-31244 in combination with sofosbuvir and daclatsavir with or without a protease inhibitor, for the treatment of hepatitis C is expected to commence in Q1, 2019.

6. Adial Pharmaceuticals Inc. (ADIL)

Lost 13.43% to close Wednesday's trading at $5.80.

News: No news

Pipeline & Near-term Catalyst:

The Company's lead product candidate is AD04, a genetically targeted therapeutic agent, for the treatment of alcohol use disorder, and opioid use disorder.

In a phase IIb trial, AD04 showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking in patients with alcohol use disorder.

A phase III clinical trial of AD04 for the potential treatment of alcohol use disorder in subjects with certain target genotypes is expected to commence in 2019.

For comments and feedback contact: editorial@rttnews.com

Follow RTT